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A live vaccine against Neospora caninum abortions in cattle 3 
Dear Editor 4 
 5 
We think there is an opportunity to debate the topic of “Why the cattle industries and 6 
associated veterinary pharmaceutical industry, veterinarians and farmers alike should not be 7 
afraid of using a live vaccine against Neospora caninum-associated abortion loss”. 8 
N. caninum has emerged as a major cause of abortion in dairy and beef cattle and it is 9 
estimated to be responsible for losses in excess of a billion dollars annually, in cattle 10 
industries worldwide [1]. Yet, after more than 25 years of research on this parasite, the control 11 
options for this disease appear to be reduced to interrupting the life cycle of this parasite. A 12 
commercial, inactivated vaccine for the prevention of bovine neosporosis was introduced to 13 
markets more than a decade ago and subsequently withdrawn from sales, presumably due to 14 
its very low efficacy [2], as observed with many other parasitic diseases [3]. 15 
The remaining options that are proposed include reproductive management, (selective 16 
culling through the use of diagnostic tools), limiting access of canids (the known definitive 17 
hosts: dog, wolf, coyote and dingo [4, 5]) and their fecal material to water and food supplies 18 
of cattle to the proper disposal of tissues produced by abortions. The sylvatic life cycle of this 19 
protozoan involves rodents, birds and many other mammals and is difficult to control [6]. An 20 
efficacious, live vaccine would seem to offer a simple and attractive alternative to these above 21 
options [7]. Fortunately, neosporosis does not appear to be a zoonotic disease [8]. 22 
N. caninum has such an intriguing adaptation to cattle as the intermediate host that 23 
vertical transmission occurs efficiently without any clinical sign, but for the occasional 24 
abortion and, sporadically, neurological clinical signs in newborn calves. Stress, genetics 25 
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(dairy breeds appearing more susceptible to infection with N. caninum than beef breeds [1]), 26 
immunosuppression (mycotoxins [9], Bovine Viral Diarrhoea virus [10]), management have 27 
all been suggested as risk factors for the expression of disease. In addition, postnatal 28 
transmission occurs, involving canids as the definitive host, allowing the parasite to complete 29 
its life cycle [11]. 30 
Costly management control options include the culling of infected animals. Hitherto 31 
no drug has been marketed to prevent either abortions or infections in cattle [6, 11], although 32 
experimentally a tachyzoite challenge could be curtailed with frequent doses of toltrazuril 33 
[12]. As the disease causes serious reproductive losses, one would expect that generous 34 
funding from the public and private sector would be available for the development of tools for 35 
the control of the disease. 36 
Many research groups previously working on the related protozoan Toxoplasma gondii 37 
drew from their expertise, methodologies and techniques to understand this economically 38 
important coccidian parasite. Continuing efforts have demonstrated that the only way to 39 
prevent abortions appears to be through exposure to the parasite before pregnancy, just as is 40 
the case with toxoplasmosis in humans and sheep [13, 14]. For many livestock diseases, live 41 
vaccines are used as effective tools for the prevention of serious disease, such as 42 
toxoplasmosis, theileriosis, babesiosis and coccidiosis [7]. Moreover, naturally attenuated 43 
strains have proven to be useful in preventing abortions in neosporosis [15, 16]. Yet, a live 44 
Neospora vaccine has not reached the market, despite the fact, that these “proof-of-concept” 45 
trials have demonstrated high efficacy against an exogenous (de-novo infection of the 46 
pregnant dam, which crosses the placenta) transplacental infection. Additional work is needed 47 
to assess the ability of such “vaccines” to prevent endogenous (recrudescence of an already 48 
established, chronic infection of the dam during pregnancy) transplacental infection; this has 49 
not yet been assessed. 50 
Infection with N. caninum during pregnancy can have different outcomes, often 51 
depending on the time point of infection and the immune status of the fetus. If fetal infection 52 
("not cow infection") occurs in the first trimester of gestation, the outcome is often abortion; 53 
transplacental transmission of the parasite is expected to be low in this time of pregnancy . 54 
However, calves born from Neospora-positive dams might continue to develop through 55 
gestation, and are either born weak, show neurological signs of disease later in development, 56 
or can also be completely unaffected [17]. In the latter case, such calves can then, in turn, give 57 
birth to N. caninum infected offspring, which are either affected by the disease or not. This 58 
complicates the situation immensely, and renders the development of a vaccine, no matter 59 
whether a live or a subunit version, a difficult task. A vaccine that can both, prevent abortion 60 
as well vertical transmission, might be difficult to achieve [18] and be seen by the industry as 61 
being too technically challenging. 62 
Another important factor that makes vaccine development in neosporosis difficult is 63 
the fact that there is no small animal laboratory model available that reliably simulates the 64 
placental environment in cattle. Ultimately, safety and efficacy need to be shown in the target 65 
species, i.e. primarily cattle. Therefore, “proof-of-concept” studies in the rodent model, 66 
although possibly an important staging point in the decision making process of the 67 
pharmaceutical industry, have to be treated with caution, and do not necessarily predict the 68 
outcomes in cattle [18], and their utility might thus be queried even on animal welfare 69 
grounds. Small ruminants, in particular sheep may provide a further model system [19]. 70 
Disadvantages that might be seen to be associated with live vaccines include the 71 
potential for reversion to pathogenicity, costly production and distribution channels, and 72 
latency in the intermediate host [7], which might also explain why no live vaccines have been 73 
commercially produced for neosporosis yet. If cattle vaccinated with a live, attenuated 74 
vaccine were to suffer abortions, this would potentially expose the vaccine manufacturer to 75 
lawsuits. Live vaccine production would likely rely on cell-culture-derived organisms the 76 
production process of which is labour intensive in its maintenance. Live vaccine production 77 
also present challenges in terms of parasite preservation and viability thereafter, although the 78 
successful production and distribution of Toxovax® (a live vaccine for the prevention of 79 
T. gondii abortions in sheep) shows this is achievable through a “made to order” process. As 80 
live vaccines might possibly be expected to result in chronic infection of the host, a residual 81 
risk exists that the life cycle could ultimately be completed again, if tissues from vaccinates 82 
was to be fed to canid definitive hosts. With Toxovax®, the tachyzoites of T. gondii appear to 83 
have lost the ability to encyst (and thus persist) in the vaccinated host; a live vaccine for 84 
N. caninum ideally would use similarly modified life stages of that parasite. Also, cattle that 85 
are vaccinated with a live isolate might be difficult to distinguish from their naturally 86 
N. caninum infected cohorts and a diagnostic approach that facilitates DIVA (Differentiating 87 
Infected from Vaccinated Animals) may be required. 88 
Molecular techniques are, however, available to distinguish N. caninum vaccinated 89 
from naturally infected animals, including the possibility for genetic characterization of 90 
isolates [20, 21]. These techniques also might give rise to the possibility of the development 91 
of live marker vaccines with gene deletions for specific proteins, which could, in turn, be used 92 
in a given serological test to distinguish those cattle thus vaccinated from those animals that 93 
were naturally infected. 94 
Currently, no vaccine composed of recombinant antigens is commercially available for 95 
diseases caused by apicomplexan parasite. However, some vaccines based on native antigens 96 
are available. CoxAbic™ is composed of affinity-purified gametocyte antigens from Eimeria 97 
maxima and confers protection to hens and their offspring against coccidiosis by transmission 98 
of specific antibodies via egg yolk [22]. Another marketed vaccine composed of soluble 99 
antigens from two Babesia species (Nobivac Piro™) confers protection against babesiosis in 100 
dogs [23]. The success of these vaccines in preventing parasitic disease provides “proof-of-101 
concept” that subunit vaccines can be produced. They are also considerably cheaper to 102 
manufacture than live vaccines and this may influence the decision-making process of the 103 
leaders of pharmaceutical companies, deciding that focus on the development of recombinant 104 
subunit vaccines is worth the trouble. 105 
While recombinant antigens may be more attractive from a financial point of view, 106 
they have, in the case of neosporosis, not yet shown similar efficacy [18]. There is also a large 107 
body of scientific evidence for apicomplexan parasites which shows the live vaccination route 108 
is still the most promising [7]. While, however, these recombinant and sub-unit approaches 109 
are being actively investigated, and further work should investigate these, the animal health 110 
and primary industry, and veterinarians should nevertheless, in the meantime, invest in the 111 
development of a live vaccine against bovine neosporosis. This seems to be an approach that 112 
could lead to an efficacious vaccine for the prevention of abortions in cattle, and should be 113 
investigated more thoroughly. 114 
Refinement of the current experimental vaccine regimes might yield vaccine 115 
candidates that are cheaper to produce: reduced doses still sufficient to induce protective 116 
immunity should be investigated, as they might also decrease the cost of production. 117 
Vaccination before puberty may be another option. Application of the vaccine onto mucosal 118 
surfaces could be an alternative as well, making for easier and cheaper application on the 119 
farm. 120 
Recent publications have calculated the considerable losses inflicted by N. caninum on 121 
cattle industries world-wide [1]. Vaccination, at least at this stage, appears to be the only 122 
viable intervention strategy that appears feasible. The development of a live vaccine against 123 
neosporosis should be pursued, in order that its benefits can be transferred as soon as possible 124 
to veterinarians and farmers in order to prevent the reproductive, productive and economic 125 
losses caused by N. caninum. 126 
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